IONS Ionis Pharmaceuticals Inc

Price (delayed)

$43.11

Market cap

$6.07B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.23

Enterprise value

$6.51B

Sector: Healthcare
Industry: Biotechnology

Ionis Pharmaceuticals is a biotechnology company based in Carlsbad, California that specializes in discovering and developing RNA-targeted therapeutics. The company has 3 commercially approved medicines: Spinraza , Tegsedi , and ...

Highlights

IONS's quick ratio has dropped by 65% since the previous quarter and by 64% year-on-year
The company's equity fell by 43% YoY and by 39% QoQ

Key stats

What are the main financial stats of IONS
Market
Shares outstanding
140.86M
Market cap
$6.07B
Enterprise value
$6.51B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
7.15
Price to sales (P/S)
8.25
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.93
Earnings
Revenue
$729.26M
EBIT
-$89.56M
EBITDA
-$74.47M
Free cash flow
$772,000
Per share
EPS
-$3.23
Free cash flow per share
$0.01
Book value per share
$6.03
Revenue per share
$5.22
TBVPS
$16.92
Balance sheet
Total assets
$2.39B
Total liabilities
$1.55B
Debt
$839.57M
Equity
$843.35M
Working capital
$1.55B
Liquidity
Debt to equity
1
Current ratio
3.65
Quick ratio
3.38
Net debt/EBITDA
-5.93
Margins
EBITDA margin
-10.2%
Gross margin
98.4%
Net margin
-61.9%
Operating margin
-23.6%
Efficiency
Return on assets
-15.5%
Return on equity
-36.4%
Return on invested capital
-3.1%
Return on capital employed
-5%
Return on sales
-12.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

IONS stock price

How has the Ionis Pharmaceuticals stock price performed over time
Intraday
1.53%
1 week
5.71%
1 month
-1.1%
1 year
-24.32%
YTD
-23.75%
QTD
-4.11%

Financial performance

How have Ionis Pharmaceuticals's revenue and profit performed over time
Revenue
$729.26M
Gross profit
$717.32M
Operating income
-$172.08M
Net income
-$451.29M
Gross margin
98.4%
Net margin
-61.9%
The operating margin has dropped by 172% year-on-year
IONS's operating income has dropped by 147% year-on-year
The gross profit is down by 36% year-on-year and by 22% since the previous quarter
IONS's revenue is down by 35% YoY and by 22% QoQ

Growth

What is Ionis Pharmaceuticals's growth rate over time

Valuation

What is Ionis Pharmaceuticals stock price valuation
P/E
N/A
P/B
7.15
P/S
8.25
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.93
The stock's price to book (P/B) is 57% less than its 5-year quarterly average of 16.2 but 14% more than its last 4 quarters average of 6.2
The company's equity fell by 43% YoY and by 39% QoQ
IONS's revenue is down by 35% YoY and by 22% QoQ
The P/S is 29% less than the 5-year quarterly average of 11.5 and 3.2% less than the last 4 quarters average of 8.4

Efficiency

How efficient is Ionis Pharmaceuticals business performance
Ionis Pharmaceuticals's return on sales has shrunk by 175% QoQ and by 136% YoY
Ionis Pharmaceuticals's ROIC has plunged by 162% from the previous quarter and by 124% YoY

Dividends

What is IONS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IONS.

Financial health

How did Ionis Pharmaceuticals financials performed over time
The total assets is 55% greater than the total liabilities
The current ratio has dropped by 65% since the previous quarter and by 63% year-on-year
IONS's quick ratio has dropped by 65% since the previous quarter and by 64% year-on-year
Ionis Pharmaceuticals's debt to equity has soared by 85% YoY and by 69% from the previous quarter
The company's equity fell by 43% YoY and by 39% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.